{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:53:22Z","timestamp":1777521202283,"version":"3.51.4"},"reference-count":21,"publisher":"Galenos Yayinevi","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"published-print":{"date-parts":[[2022,6,29]]},"DOI":"10.4274\/tjo.galenos.2021.37075","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:50:49Z","timestamp":1656510649000},"page":"179-185","source":"Crossref","is-referenced-by-count":9,"title":["Survey of Intravitreal Injection Preferences for the Treatment of Age-Related Macular Degeneration and Macular Edema Among Members of the Turkish Ophthalmological Association"],"prefix":"10.4274","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-4603","authenticated-orcid":false,"given":"V. Levent","family":"Karaba\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6716","authenticated-orcid":false,"given":"Ecem","family":"\u00d6nder Toku\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-7512","authenticated-orcid":false,"given":"Figen","family":"\u015eermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"QD","year":"2012","unstructured":"1. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.","journal-title":"Ophthalmology"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial","volume":"317","author":"IU","year":"2017","unstructured":"2. Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017;317:2072-2087.","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077.","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"DM","year":"2006","unstructured":"4. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.","journal-title":"N Engl J Med"},{"key":"ref4","unstructured":"5. Highlights of Prescribing Information: Avastin 2017 [cited 2021 March 20] Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125085."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Cohen D. Why have UK doctors been deterred from prescribing Avastin? BMJ. 2015;350:h1654.","DOI":"10.1136\/bmj.h1654"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4274\/tjo.galenos.2021.18794","article-title":"Survey of Intravitreal Injection Techniques and Treatment Protocols Among Members of the Turkish Ophthalmological Association","volume":"51","author":"\u00d6nder Toku\u00e7","year":"2021","unstructured":"7. \u00d6nder Toku\u00e7 E, Karaba\u015f VL, \u015eermet F. Survey of Intravitreal Injection Techniques and Treatment Protocols Among Members of the Turkish Ophthalmological Association. Turk J Ophthalmol. 2021;51:373-380.","journal-title":"Turk J Ophthalmol"},{"key":"ref7","unstructured":"8. Singh RP. 2019 Global Trends in Retina Survey, Available at: https:\/\/www.asrs.org\/content\/documents\/2019-global-trends-survey-for-website.pdf [cited 2021 March 20]."},{"key":"ref8","unstructured":"9. Eliot D. 2020 Global Trends in Retina Survey, Available at: https:\/\/www.asrs.org\/content\/documents\/2020-global-trends-in-retina-survey-highlights-for-website.pdf [cited 2021 March 20]."},{"key":"ref9","unstructured":"10. Subhi Y, Kjer B, Munch IC. Prefilled syringes for intravitreal injection reduce preparation time. Dan Med J. 2016;63:A5214."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Michaud JE, Sigg J, Boado L, Momm J, Weber C, Alete D, Peregi E, Picci M. Ranibizumab pre-filled syringe approved in the European union: innovation to improve dose accuracy, reduce potential infection risk, and offer more efficient treatment administration. Invest Ophthalmol Vis Sci. 2014;55:1949.","DOI":"10.1167\/iovs.14-15564"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00417-019-04569-8","article-title":"Off-label use of bevacizumab for wet age-related macular degeneration in Europe","volume":"258","author":"Bro","year":"2020","unstructured":"12. Bro T, Derebecka M, J\u00f8rstad \u00d8K, Grzybowski A. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol. 2020;258:503-511.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref12","unstructured":"13. Singh RP. 2018 Global Trends in Retina Survey, Available at: https:\/\/www.asrs.org\/content\/documents\/2018-global-trends-in-retina-survey-highlights-website.pdf [cited 2021 March 20]."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)","volume":"242","author":"Schmidt-Erfurth","year":"2019","unstructured":"14. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, Wolf S, Loewenstein A. Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242:123-162.","journal-title":"Ophthalmologica"},{"key":"ref14","unstructured":"15. Rezaei KA. 2015 Global Trends in Retina Survey 2015, Available at: https:\/\/www.asrs.org\/content\/documents\/2015_global_trends_in_retina_survey_-_for_website.pdf [cited 2021 March 20]."},{"key":"ref15","unstructured":"16. Republic of Turkey Ministry of Health. Turkish Medicines and Medical Devices Agency. Available at: https:\/\/www.titck.gov.tr\/mevzuat\/endikasyon-disi-ilac-kullanimi-kilavuzu-27122018172948"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial","volume":"123","author":"JA","year":"2016","unstructured":"17. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123:1351-1359.","journal-title":"Ophthalmology"},{"key":"ref17","unstructured":"18. Ng DS, Kwok AK, Chan CW, Li WW. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients. Hong Kong Med J. 2012;18:488-495."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/ceo.12489","article-title":"Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab","volume":"43","author":"Das","year":"2015","unstructured":"19. Das T, Volety S, Ahsan SM, Thakur AK, Sharma S, Padhi TR, Basu S, Rao ChM. Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab. Clin Exp Ophthalmol. 2015;43:466-473.","journal-title":"Clin Exp Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1345\/aph.1L270","article-title":"Bevacizumab sterility in multiple doses from a single-use vial","volume":"42","author":"Ornek","year":"2008","unstructured":"20. Ornek K, Karahan ZC, Ergin A, Tekeli A, Tekeli O. Bevacizumab sterility in multiple doses from a single-use vial. Ann Pharmacother. 2008;42:1425-1428.","journal-title":"Ann Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4103\/0301-4738.99855","article-title":"Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial","volume":"64","author":"Khan","year":"2016","unstructured":"21. Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64:694-696.","journal-title":"Indian J Ophthalmol"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:02:36Z","timestamp":1721998956000},"score":1,"resource":{"primary":{"URL":"https:\/\/oftalmoloji.org\/articles\/doi\/tjo.galenos.2021.37075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,29]]},"published-print":{"date-parts":[[2022,6,29]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2021.37075","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]}}}